Biotechnology

Found 39,845 articles

• Sun Genomics Launches World's First Fully Customizable MultivitaminFloré Multi-V Released as the Company Participates in the Institute for Functional Medicine's (IFM) Industry-Leading Conference

  5/31/2023

  Sun Genomics, a leader in gut health testing specializing in made-to-order probiotics based on an individual’s gut microflora, has launched the world’s first fully customizable multivitamin, Floré Multi-V.

• Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June 2023

  5/31/2023

  ValnevaSE, a specialty vaccine company, announced that its senior management will attend the Jefferies Healthcare Conference, Goldman Sachs Annual Global Healthcare Conference and the Stifel European Healthcare Conference.

• NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET

  5/31/2023

  NanoViricides, Inc., announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET.

• Valneva Announces the Availability of Documentation for its Shareholder Meeting

  5/31/2023

  ValnevaSE, a specialty vaccine company, announced the availability of documentation for its Combined General Meeting to be held on June 21, 2023 at 2 p.m. CEST, at the hotel InterContinental Lyon – Hotel Dieu, 20 Quai Jules Courmont, 69002 Lyon.

• CARGO Therapeutics to Present at the Jefferies Global Healthcare Conference 

  5/31/2023

  CARGO Therapeutics, Inc., a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, announced that management will present at the upcoming Jefferies Global Healthcare Conference on Friday, June 9, 2023 at 9:00 a.m. Eastern Time in New York City.

• Change in the number of shares and votes in Medivir AB (publ)

  5/31/2023

  Medivir AB announces that the number of shares and votes in Medivir has changed during May 2023 as a result of the previously announced share issue of 970,500 shares of series C and the reclassification of 105,750 shares of series C into ordinary shares, which was carried out as part of the long-term incentive program for key employees within the Medivir group adopted by the annual general meeting held on 4 May 2023.

• The Caris Precision Oncology Alliance Welcomes Leading Cancer Center

  5/31/2023

  Caris Life Sciences® announced that Memorial Sloan Kettering Cancer Center, one of the world's premier cancer centers, has joined the Caris Precision Oncology Alliance™ and will collaborate with Caris on various research projects.

• Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer

  5/31/2023

  Hinge Bio, Inc., a privately-held biotechnology company, announced that Juha Punnonen, M.D., Ph.D. has joined the company as Chief Development Officer.

• BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th ECFC

  5/31/2023

  BiomX Inc. announced that the Company will present Part 1 data from its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during the Late-Breaking Science Session at 46th European Cystic Fibrosis Conference, which is being held June 7-10th, 2023, in Vienna, Austria.

• DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT)

  5/31/2023

  DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced that the DermTech Melanoma Test has tested more than 200,000 suspicious pigmented lesions.

• Asieris' progress in MIBC receives renewed attention with its inclusion in ASCO 2023

  5/31/2023

  Asieris Pharmaceuticals announced the phase I clinical data of ANTICIPATE Study was published for the first time at the 2023 American Society of Clinical Oncology annual meeting in Chicago.

• Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

  5/31/2023

  Design Therapeutics, Inc. reported that management will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 3:30 p.m. ET in NYC.

• SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy

  5/31/2023

  SNIPR Biome ApS announces positive interim clinical results from its Phase 1 clinical trial with SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract.

• Third-Party Valuation Firm Provides Estimated Valuation of ByoPlanet's (A Subsidiary Of Plandai – $PLPL) Business and Assets

  5/31/2023

  ByoPlanet, a wholly owned subsidiary of Plandai Biotechnology, Inc., a leading innovator in revolutionary cleaning technology, announced the completion of a third-party valuation firm's estimates of ByoPlanet's business and assets based on ByoPlanet's unaudited financial statements and internal projections.

• Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

  5/31/2023

  Coave Therapeutics announces the positive 12-month results from its Phase I/II trial evaluating the safety and efficacy of its innovative gene therapy, CTx-PDE6b, for retinitis pigmentosa caused by bi-allelic mutations in the PDE6B gene.

• Telesis Bio Secures Financing of $28.0 Million

  5/31/2023

  Telesis Bio Inc. announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28.0 million in gross proceeds to Telesis Bio through a private placement of redeemable convertible preferred stock.

• Satellos Bioscience Announces 2023 Q1 Financial Results and Operational Highlights

  5/31/2023

  - $55 million equity financing closed - Resourced to advance lead drug candidate into clinical trials

• Umoja Biopharma to Present at the 2023 BIO International Convention

  5/31/2023

  Umoja Biopharma, Inc. announced that the Company will present on its mission, pipeline, technological platforms, and partnering approach at the 2023 BIO International Convention taking place June 5-8, 2023 in Boston, MA.

• BioHarvest Reports Q1 2023 Results Demonstrating Strong Year Over Year Growth

  5/31/2023

  BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company") announces that it has released Q1 2023 results.

• Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023

  5/31/2023

  Indaptus Therapeutics, Inc. announced today that CEO Jeffrey A. Meckler will present a corporate overview at the Jefferies Healthcare Conference 2023.